Trade Spyre Therapeutics Inc. - SYRE CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.1600 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 20.39 |
| Open | 20.95 |
| 1-Year Change | 78.77% |
| Day's Range | 20.95 - 22.56 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 21, 2025 | 22.2000 | 1.4200 | 6.83% | 20.7800 | 22.7200 | 20.7800 |
| Jan 17, 2025 | 20.5400 | 0.0400 | 0.20% | 20.5000 | 21.0700 | 20.2800 |
| Jan 16, 2025 | 20.4700 | -0.3500 | -1.68% | 20.8200 | 21.6900 | 20.3400 |
| Jan 15, 2025 | 21.5800 | -0.2500 | -1.15% | 21.8300 | 21.9800 | 20.9700 |
| Jan 14, 2025 | 20.7400 | -0.9100 | -4.20% | 21.6500 | 21.6500 | 20.3100 |
| Jan 13, 2025 | 21.4200 | -1.3900 | -6.09% | 22.8100 | 22.8100 | 20.4500 |
| Jan 10, 2025 | 22.4050 | -0.7550 | -3.26% | 23.1600 | 23.1600 | 21.5450 |
| Jan 8, 2025 | 23.9700 | -0.0600 | -0.25% | 24.0300 | 24.3200 | 23.6000 |
| Jan 7, 2025 | 24.2800 | 0.3200 | 1.34% | 23.9600 | 25.6800 | 23.9500 |
| Jan 6, 2025 | 24.3000 | -0.2500 | -1.02% | 24.5500 | 25.1400 | 24.1700 |
| Jan 3, 2025 | 24.2400 | 0.6300 | 2.67% | 23.6100 | 24.6600 | 23.5600 |
| Jan 2, 2025 | 23.7500 | 0.2500 | 1.06% | 23.5000 | 24.3200 | 22.6000 |
| Dec 31, 2024 | 23.2400 | 0.7000 | 3.11% | 22.5400 | 23.4000 | 22.5100 |
| Dec 30, 2024 | 22.4500 | -0.5600 | -2.43% | 23.0100 | 23.3900 | 22.3000 |
| Dec 27, 2024 | 23.5800 | -0.3300 | -1.38% | 23.9100 | 24.0600 | 23.0400 |
| Dec 26, 2024 | 23.9400 | 1.3700 | 6.07% | 22.5700 | 24.0200 | 22.5700 |
| Dec 24, 2024 | 23.2400 | -0.2800 | -1.19% | 23.5200 | 23.5900 | 22.5100 |
| Dec 23, 2024 | 23.4700 | -0.0500 | -0.21% | 23.5200 | 23.6800 | 22.7200 |
| Dec 20, 2024 | 23.8000 | 1.3300 | 5.92% | 22.4700 | 24.6900 | 22.2700 |
| Dec 19, 2024 | 23.0200 | -0.0900 | -0.39% | 23.1100 | 23.3900 | 22.4900 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Aeglea Bio Therapeutics Company profile
About Aeglea Bio Therapeutics Inc
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing human enzyme therapeutics to benefit people with rare metabolic diseases. The Company’s product candidates include pegzilarginase and AGLE-177. The Company's lead product candidate, pegzilarginase, is a recombinant human arginase one that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase one Deficiency. Its engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. The Company is evaluating Pegzilarginase in a global pivotal Phase III PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and in a Phase II open-label extension study for patients with Arginase One Deficiency. Its AGLE-177, is a novel PEGylated, or polyethylene glycol modified, human enzyme engineered to reduce Homocystinuria.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Aeglea Bio Therapeutics Inc revenues increased from $0K to $18.7M. Net loss decreased 19% to $65.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -$1.52 to -$1.33.
| Industry: | Bio Therapeutic Drugs |
221 Crescent Street
Suite 105
WALTHAM
MASSACHUSETTS 02453
US
News
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024People also watch
Still looking for a broker you can trust?
Join the 680,000+ traders worldwide that chose to trade with Capital.com